Pulmonary Hypertension Pathophysiology and Management

Pulmonary hypertension (PH) is characterised by pathological elevation of pressure in the pulmonary circulation, driven by endothelial dysfunction, smooth muscle proliferation and inflammatory signalling. Key mediators include reduced nitric oxide bioavailability, overexpression of endothelin-1 and imbalanced bone morphogenetic protein signalling, often compounded by heritable mutations in receptors such as BMPR2. These insults promote remodelling of small pulmonary arteries, increasing pulmonary vascular resistance and mean pulmonary arterial pressure, which in turn impose a chronic pressure overload on the right ventricle. Clinical presentation spans dyspnoea, fatigue and syncope, progressing to right heart failure if untreated. Diagnosis relies on echocardiographic probability assessment followed by definitive right heart catheterisation. Risk stratification incorporates haemodynamics, functional class and biomarkers to guide treatment. Management has evolved from general measures—oxygen therapy, diuretics and anticoagulation—to disease-specific agents targeting vasoconstriction and vascular remodelling: prostanoids, endothelin receptor antagonists, phosphodiesterase type 5 inhibitors and soluble guanylate cyclase stimulators. In chronic thromboembolic PH, surgical pulmonary endarterectomy remains curative for operable disease, while balloon pulmonary angioplasty and medical therapy serve in inoperable cases. Emerging approaches include anti-inflammatory immunotherapy and gene-based interventions aimed at restoring endothelial homeostasis. A multidisciplinary model ensures integration of diagnostics, tailored pharmacotherapy and interventional procedures to improve long-term outcomes.

Research from Nature Portfolio

Recent whole-genome sequencing efforts in pulmonary arterial hypertension cohorts have uncovered rare pathogenic variants in genes beyond the canonical BMPR2 pathway, implicating ATP13A3, AQP1 and SOX17 in endothelial function and vascular integrity. These discoveries broaden our understanding of inherited susceptibility and point to novel molecular targets for precision medicine. Complementary mechanistic studies have delineated how tumour necrosis factor-α suppresses BMPR-II expression and activates sheddase-mediated receptor cleavage in pulmonary artery smooth muscle cells, triggering a shift towards pro-proliferative NOTCH2 signalling. In preclinical models, antagonism of this inflammatory axis restores balanced bone morphogenetic protein and NOTCH pathways, reverses pulmonary vascular remodelling and ameliorates right ventricular dysfunction, signalling a promising translational route for immunomodulatory therapy.

Pulmonary Hypertension Pathophysiology and Management publication trend

The graph below shows the total number of articles in pulmonary hypertension pathophysiology and management across all publications each year (not limited to Nature Index journals).

Technical terms

Mean pulmonary arterial pressure (mPAP): The average pressure in the pulmonary artery during one cardiac cycle, used to define pulmonary hypertension.

Pulmonary vascular resistance (PVR): A calculation of resistance across the pulmonary vasculature, derived from pressure gradients and cardiac output.

Bone morphogenetic protein receptor type II (BMPR2): A transforming growth factor-β receptor whose loss of function underlies many heritable cases of pulmonary arterial hypertension.

Right heart catheterisation: An invasive diagnostic procedure measuring pressures in the right atrium, right ventricle and pulmonary artery to confirm pulmonary hypertension definitively.

References

1. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. European Respiratory Journal (2019).
2. Chronic thromboembolic pulmonary hypertension. European Respiratory Journal (2019).
3. Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. Nature Communications (2018).
4. TNFα drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling. Nature Communications (2017).
5. Echocardiographic assessment of pulmonary hypertension: a guideline protocol from the British Society of Echocardiography. Echo Research & Practice (2018).